ReviewEXCLI journal2010
Human paraoxonase 2.
Review in EXCLI journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 8 citations in OpenAlex.
- The Paraoxonase (International journal of molecular sciences · 2025Review
- Molecular Structure of Paraoxonase-1 and Its Modifications in Relation to Enzyme Activity and Biological Functions-A Comprehensive Review.International journal of molecular sciences · 2024Review
- Paraoxonases at the Heart of Neurological Disorders.International journal of molecular sciences · 2023Review
- Human Paraoxonase-2 (PON2): Protein Functions and Modulation.Antioxidants (Basel, Switzerland) · 2021Review
- Association between human paraoxonase 2 protein and efficacy of acetylcholinesterase inhibiting drugs used against Alzheimer's disease.PloS one · 2021Article
- The Structure and Function of Paraoxonase-1 and Its Comparison to Paraoxonase-2 and -3.Molecules (Basel, Switzerland) · 2020Review
- Association of polymorphism of ser311cys paraoxonase-2 gene with type 2 diabetes mellitus in iran.International journal of preventive medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human paraoxonase 2 (PON2), which is a member of the paraoxonase family, possesses unique properties that distinguish it from PON1 and PON3. PON2 is ubiquitously expressed in many different tissue types and is highly expressed in the vital organs, such as the heart and lungs. Early research revealed that PON2 is exclusively intracellularly found, wherein it functions as an anti-oxidative protein by reducing intracellular and local oxidative stress. Studies in the last five years have demonstrated that PON2 protects against atherosclerosis by preventing low-density lipoprotein (LDL) oxidation, reversing the oxidation of mildly oxidised LDL, inhibiting monocyte chemotaxis, and increasing cholesterol efflux. Recently, emerging evidence has proposed that PON2 is an anti-atherosclerotic and may be associated with cardiovascular disease (CVD). The number of investigations concerning the relationship between two common
Indexed as
Identifiers
29255397PMC5698900W2462190360What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.